Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Milena M. McLaughlin; Abeer T. Ammar; Lana Gerzenshtein; Kimberly K. Scarsi

doi:10.1007/s40261-015-0275-9

Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Milena M. McLaughlin, Abeer T. Ammar, Lana Gerzenshtein, Kimberly K. Scarsi

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.

Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.

Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.

Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

Original language	English (US)
Pages (from-to)	275-280
Number of pages	6
Journal	Clinical Drug Investigation
Volume	35
Issue number	4
DOIs	https://doi.org/10.1007/s40261-015-0275-9
State	Published - Mar 21 2015

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s40261-015-0275-9

Cite this

@article{aae6acd732994f8d8c2d5aa9482dd68d,

title = "Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration",

abstract = "Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.",

author = "McLaughlin, {Milena M.} and Ammar, {Abeer T.} and Lana Gerzenshtein and Scarsi, {Kimberly K.}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer International Publishing Switzerland.",

year = "2015",

month = mar,

day = "21",

doi = "10.1007/s40261-015-0275-9",

language = "English (US)",

volume = "35",

pages = "275--280",

journal = "Clinical Drug Investigation",

issn = "1173-2563",

publisher = "Adis International Ltd",

number = "4",

}

TY - JOUR

T1 - Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

AU - McLaughlin, Milena M.

AU - Ammar, Abeer T.

AU - Gerzenshtein, Lana

AU - Scarsi, Kimberly K.

PY - 2015/3/21

Y1 - 2015/3/21

N2 - Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

AB - Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

UR - http://www.scopus.com/inward/record.url?scp=84925495835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925495835&partnerID=8YFLogxK

U2 - 10.1007/s40261-015-0275-9

DO - 10.1007/s40261-015-0275-9

M3 - Article

C2 - 25691260

AN - SCOPUS:84925495835

SN - 1173-2563

VL - 35

SP - 275

EP - 280

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

IS - 4

ER -

Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this